Back to Events List


Members' Exchange Forum 2017

County Hall, Riverside Building, Belvedere Road, London, SE1 7PB
Thursday 07 September 2017, 1:30 PM - 6:30 PM

Getting Real with Real World Evidence

How can we, as business intelligence professionals, derive insight from the approaches and sources of Real World Evidence (RWE)? We will explore the different types of evidence and the evolving ways in which data is collected and used. What are the differences between Real World Data (RWD), Real World Evidence (RWE) and Real World Insight (RWI)? What are the challenges in this area and what is the value for pharma?

NEW - View the Chair's observations/review of the event (available to all)

View the final programme and speaker presentations (available to BHBIA members only)


This half day meeting will begin at 2.00pm and will be held at County Hall, Riverside Building, Belvedere Road, London, SE1 7PB (view map). The Members’ Exchange Forum is an opportunity for us to get together and catch up on key issues impacting our work, as well as with each other.



14.00 Introductions and Objectives
Rob Heathcote, BHBIA Board Member and Head of Product Management - QuintilesIMS and David Physick, Chair and Founding Associate - SEA Consultancy

14.10 Real World Insight and Primary Market Research: a synergistic approach for more  actionable insights
Sarah Phillips, Senior Principal - QuintilesIMS

What are the differences between Real World Data (RWD), Real World Evidence (RWE) and Real World Insight (RWI)? An overview of the different types of evidence that can be generated, the challenges in
 generating evidence and how Real World Insight can be used to augment primary market research studies to deliver a deeper understanding of why particular behaviours and patterns exist. This session will also explain how real world data is an extremely valuable asset for commercial insight as well as for scientific purposes and how the insights provide support across all functions of a pharma company, with each function asking different questions of the evidence.

14.30 Institutionalising Real World Data
Simon Tilley, Life Science Director Northern Europe, SAS

Real World Data is incredibly diverse, as are the uses to which it can be put, but one thing is for certain – there is a set of capabilities that consistently enable it to be ingested and made valuable right across the business value chain.

14.50 Pharma Company Perspective
Claire Methven, Real World Evidence Manager - Janssen

With the increasing need to generate and utilise RWE to improve patient outcomes and to support the access to innovative medicines,  pharma is having to adapt to generate evidence in addition to randomised controlled trials RCTs.
What type of evidence is being generated to support access of innovative medicines?
How do we ensure the RWE generated is robust and acceptable?
How can we utilise the RWE/RWI generated by BI/MR to address evidence gaps?

15.10 Networking tea and coffee break

15.40 Summary/reflections on what we have heard so far
David Physick, Chair

15.50 How Real World Evidence can change the way pharma interact with their customers to demonstrate value
Steve How - Business Development Director, Wilmington Healthcare

As NHS budgets tighten and CCGs come under pressure to meet new prescribing targets, improve outcomes and save money, the need for pharma to develop strong value propositions for its products has never been greater. To demonstrate the value of its products, pharma also needs to think beyond traditional clinical trial data to provide real world evidence on issues such as how its drugs perform within specific cohorts of patients and their effectiveness over time. Pharma must also adopt a tailored engagement approach to CCGs that takes account of their local prescribing priorities and challenges, and demonstrates real value on a local as well as a national level.
Understand how to use real world evidence to demonstrate the value of your product to improve adherence, resulting in better patient outcomes, whilst maintaining your product’s place on formularies, and sustaining ROI on brands.

16.10 The power of RWE to change landscape – now and in the future
Anita Agier - Director, Head of Real World Evidence, GfK

RWE has the power to change landscapes: Anita will discuss a longitudinal RWE study (that is well-known in the industry) and how it has changed the landscape.
RWE now: How it is currently used, with examples 
RWE in the future: 
- How we are going to get there?
- How it will be used
- Real data showing examples
And how BI skills need to adapt to cater to these changes

16.30 Panel Discussion followed by closing Comments from the Chair

17.00 BHBIA Announcements & close

17.15 Drinks reception

Click here to view speaker biographies

Delegate Fee - £75 + VAT 

PLEASE NOTE: This is a MEMBERS ONLY EVENT. Price includes ticket to the Summer Evening Event, so you are not required to book separately for the evening. However if you are unable to attend the Evening event, please select the relevant ticket type to enable us to cater appropriately.

7th September GDPR Seminar, Members Exchange Forum and Summer Evening Event Booking Options for Members:

GDPR Seminar, Members Exchange Forum & Summer Evening Event

£120 + VAT

GDPR Seminar & Members Exchange Forum

£120 + VAT

GDPR Seminar & Summer Evening Event

£120 + VAT

GDPR Seminar Only

£95 + VAT

Members Exchange Forum & Summer Evening Event

£75 + VAT

Members Exchange Forum Only

£75 + VAT

Summer Evening Event Only

£75 + VAT

BOOKINGS NOW CLOSED. If you have a query with an existing booking please email

Please note any bookings made after 5pm on the 1st September will not be listed in the onsite delegate list. Bookings close at 12noon on the 5th September.